SUO 2019: Novel Systemic Therapies in Penile Cancer
SUO 2019 novel systemic therapies in penile cancer, neoadjuvant chemotherapy for penile squamous cell cancer (PSCC), immune checkpoint blockade therapy,
SUO 2019 novel systemic therapies in penile cancer, neoadjuvant chemotherapy for penile squamous cell cancer (PSCC), immune checkpoint blockade therapy,
At the 2025 UCSF-UCLA PSMA Conference, Michael Hofman presents the PRIMARY score for PSMA PET in prostate cancer diagnosis. He explains how PSMA PET complements…
Zachary Klaassen speaks with Oliver Sartor about treatment intensification in metastatic hormone-sensitive prostate cancer, focusing on triplet therapy selection. Dr. Sartor traces the evolution from…
Zachary Klaassen speaks with Matthew Cooperberg about the integration of OnQ™ Prostate assisted Focal One® Robotic HIFU for prostate cancer treatment. Dr. Cooperberg discusses how…
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Alan…
Pedro Barata interviews Scott Tagawa about radioligand therapy research, focusing on actinium-225 PSMA antibody constructs. Dr. Tagawa explains that antibodies like rosopatamab offer advantages over…
At the 2025 UCSF-UCLA PSMA Conference, Tanya Dorff addresses treatment sequencing in advanced prostate cancer. She notes PARP inhibitors show superior efficacy when used early…
At the 2025 UCSF-UCLA PSMA Conference, Matthew Rettig discusses real-world PSMA radioligand therapy usage in the VA healthcare system. He highlights VA patients are older…
At the 2025 UCSF-UCLA PSMA Conference, Wolfgang Fendler discusses German early access programs for lutetium-PSMA therapy. He highlights five key contributions: actinium-PSMA alpha therapy data;…
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: A.…
Ashish Kamat speaks with Nimira Alimohamed about the evolution of circulating tumor DNA (ctDNA) in muscle invasive bladder cancer management. Dr. Alimohamed explains that current…